Alector Stock Price, News & Analysis

Alector (ALEC) reveals its clinical and research priorities for 2021, focusing on advancing its pipeline in neurodegenerative disorders. Key developments include the Phase 3 trial of AL001 for frontotemporal dementia and a Phase 2 trial for Alzheimer’s disease. Alector has a strong financial position with over $400 million in cash. Upcoming highlights include updated data from the AL001 Phase 2 study and the initiation of trials for AL101 and AL002 in 2021. The company also continues to monitor COVID-19 impacts on clinical operations and patient recruitment.

Alector, a clinical-stage biotechnology company focused on immuno-neurology, announced that Dr. Sabah Oney will speak at the Stifel 2020 Virtual Healthcare Conference on November 18, 2020, at 4:40 p.m. ET. The event will be accessible via a live webcast on Alector's investor website, with a replay available for 30 days post-event. Alector is developing innovative therapies targeting the immune system to address neurodegenerative diseases, including frontotemporal dementia and Alzheimer’s, emphasizing a novel approach to treating these conditions.

Alector, Inc. (NASDAQ: ALEC) announced its Q3 2020 financial results, reporting collaboration revenue of $5.9 million, a significant increase from $2.7 million in Q3 2019. The net loss was $52.7 million, up from $31.7 million in the prior year. The company is advancing its clinical pipeline, with a Phase 3 trial for AL001 targeting frontotemporal dementia and plans to initiate a Phase 2 trial for AL002 in Alzheimer's disease. Alector maintains a strong cash position of $461.7 million, expected to fund operations through 2022.

Alector, Inc. (Nasdaq: ALEC) announced an interim ruling from an independent arbitrator favoring the company in its arbitration proceedings with Dr. Asa Abeliovich. The arbitrator found Dr. Abeliovich liable for breach of his consulting agreement and document destruction, leading to potential damages and sanctions. The arbitration was initiated in June 2019 concerning the misuse of confidential information. Alector aims to resolve this matter efficiently, reaffirming Dr. Abeliovich's obligations towards the company.

Alector, Inc. (Nasdaq: ALEC), a biotechnology company specializing in immuno-neurology, announced its participation in two upcoming virtual scientific meetings to discuss its AL008 development program. AL008 is an investigational antibody targeting the CD47-SIRP-alpha pathway, designed to enhance anti-tumor immunity. Presentations will be made by key team members at the Macrophage-Directed Therapies Summit on October 28 and the CD47|SIRPα Summit on November 4-5, 2020. These events aim to showcase Alector's innovative approach and its commitment to developing effective cancer treatments.

Alector, a clinical-stage biotechnology company focused on immuno-neurology, will host fireside chats at two upcoming virtual investor conferences. The events will take place on September 10, 2020, at the Citi’s 15th Annual BioPharma Virtual Conference, and on September 14, 2020, at the Morgan Stanley 18th Annual Global Healthcare Conference. Live webcasts will be accessible on Alector's Investors page, with replays available for 30 days post-event. Alector aims to address neurodegenerative diseases through its innovative therapeutic approaches targeting immune dysfunction.

Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology firm specializing in immuno-neurology, announced that Chief Business Officer Sabah Oney, Ph.D., will speak at the BTIG Virtual Biotechnology Conference on August 11, 2020, at 11:00 a.m. ET. The event aims to discuss Alector's innovative approaches to treating neurodegenerative diseases by targeting immune dysfunction. A live webcast will be available on the company’s website, with a replay accessible for 30 days post-event.

Alector, a clinical-stage biotechnology company, announced positive preliminary results from the Phase 1b and Phase 2 studies of its investigational drug AL001 for treating frontotemporal dementia with a progranulin gene mutation (FTD-GRN). AL001 demonstrated general safety, restoring plasma progranulin levels to normal in all participants, with many showing decreased neurofilament light chain (NfL) levels. The pivotal Phase 3 study of AL001 commenced in July 2020, aiming to evaluate its efficacy in symptomatic and pre-symptomatic patients.

Alector, a clinical-stage biotechnology company focused on immuno-neurology, announced management participation in a virtual fireside chat at the Goldman Sachs 41st Annual Global Healthcare Conference on June 10, 2020, at 3:50 p.m. ET. The live webcast can be accessed on Alector's Investors page, with a replay available for 30 days post-event. Alector's approach targets immune dysfunction in neurodegenerative diseases, specifically in frontotemporal dementia and Alzheimer's disease, aiming to repair genetic mutations affecting the brain's immune response.